Vertex - Class A opened higher at $18.02, compared with its previous close of $17.83. In the last trading session, the stock traded between $17.62 and $18.22. It showed a sideways intraday trend.
An investment of $100 made 5 years ago in Vertex - Class A is now worth
$ 82.53
Resulting in a loss of
$ 17.47 (17.47%)
Note: Past profits do not guarantee future returns.
Rating from 7 Analysts
Today's Change
$-0.09 (-0.49%)
Day High
$18.22
Day Low
$17.62
Day Open
$18.02
Prev Close
$17.83
Volume
11,23,663
1W Return
11.57%
1M Return
37.49%
3M Return
45.11%
6M Return
27.56%
1Y Return
-9.70%
Market Cap ($ Mn)
1,421
PE Ratio
1,422.50
PB Ratio
9.53
PEG Ratio
-
ROE
3.13%
ROCE
0.35%
EPS (TTM)
$-0.29
1 Week
11.57%
1 Month
37.49%
3 Months
45.11%
6 Months
27.56%
9 Months
38.29%
Vertex Q3FY26 Results: EPS beats at 26 cents, sales top $213 million
Adjusted EPS of 26 cents beat market estimates of 22 cents. Q3 sales of $213.275 million exceeded expectations of $209.297 million. FY26 sales guidance raised to $828.900 million-$830.900 million. Piper Sandler raised price target to $20; Needham raised target to $30.
7 days agoVertex Inc appoints three executives to lead global growth and AI strategy
Vertex Inc strengthens its executive team with three key hires: Chatelle Lynch as CPO, Carlos Mercuriali as SVP for Europe, and Bala Chandran as CPTO. These appointments support the company's AI-first strategy and expansion in regulated markets.
3mo agoVertex Q2FY26: Revenue beats, EBITDA surges on cloud growth
Vertex Inc. delivered solid Q2FY26 results with $204 million in revenue and $51 million in adjusted EBITDA, driven by 17.9% cloud growth and operational discipline.
3mo agoVertex Q3 Results: Sales guidance misses $211.7M estimates
Vertex Pharmaceuticals guided Q3 sales to $208M-$211M, missing the $211.7M analyst estimate. The narrow miss suggests modest revenue pressure, with the upper guidance bound closely tracking consensus expectations.
3mo agoVertex narrows FY26 sales guidance to $825M-$830M
Vertex Pharmaceuticals tightens its FY2026 sales guidance to $825.000M-$830.000M, down from a wider $823.500M-$831.500M range. The revised midpoint remains at $827.500M, closely tracking the $827.269M consensus estimate, indicating reduced uncertainty rather than a change in growth trajectory.
3mo agoVertex Research Reveals $1M+ Annual Losses From Indirect Tax Compliance Gaps
Vertex, Inc. released research on July 30, 2026, outlining the 'Decision-to-Defense' era in indirect tax compliance. The study, based on surveys of over 2,100 decision-makers, identifies 'Defensibility Drift' and 'CompOps Drag' as major hurdles. Key findings include 58% of enterprises facing complex audits and only 12% achieving full system integration. Consequently, 1 in 3 US enterprises lose $1M+ annually due to conservative reporting and compliance gaps.
3mo ago| Stock | LTP | Change % | Market Cap | PE |
|---|---|---|---|---|
| $521.13 | -2.26% | $38,69,975.87M | 28.61 | |
| $172.40 | +2.12% | $3,97,675.94M | 160.64 | |
| $128.38 | +8.82% | $3,88,187.23M | 25.87 | |
| $234.10 | +0.15% | $2,87,592.79M | 28.43 | |
| $334.47 | +2.49% | $2,73,854.67M | 323.12 | |
| $248.22 | +1.51% | $2,34,597.93M | 20.94 | |
| $229.06 | +1.46% | $2,34,542.55M | 3,970.91 | |
| $149.26 | +1.81% | $1,80,374.29M | 103.31 | |
| $218.01 | +2.12% | $1,79,422.23M | 23.42 | |
| $253.66 | -1.88% | $1,49,846.35M | 15.14 | |
| $70.68 | +0.90% | $1,44,321.35M | 17.29 | |
| $306.36 | +0.30% | $1,20,938.37M | 26.28 |
An investment of $100 made 5 years ago in Vertex - Class A is now worth
$ 82.53
Resulting in a loss of
$ 17.47 (17.47%)
Note: Past profits do not guarantee future returns.
